Cellular therapies are revolutionizing the treatment landscape for lung cancer, presenting new opportunities for patient care. At the CURE Educated Patient® Lung Cancer Summit, Dr. Adam J. Schoenfeld, a prominent oncologist at Memorial Sloan Kettering Cancer Center, shared insights into the evolution and potential of these therapies. His discussion emphasized a critical view: lung cancer is not a monolithic disease, and treatments must be tailored to the unique biology of each tumor.
The Complexity of Lung Cancer
Dr. Schoenfeld highlighted the multifaceted nature of lung cancer, which necessitates a personalized approach to treatment. While immunotherapy and targeted therapies have achieved considerable success, many patients still face challenges, especially following disease progression. Emerging cellular therapies aim to bridge this gap by harnessing the body’s immune system to combat cancer more effectively.
Categories of Adoptive T-Cell Therapies
Three primary types of adoptive T-cell therapies were discussed: tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor (TCR) therapy, and chimeric antigen receptor (CAR)-T therapy. These innovative approaches utilize living immune cells modified to enhance their ability to identify and destroy cancer cells. Despite the complexity and time required for their preparation, these therapies hold the promise of sustained efficacy after a single infusion.
TIL Therapy: Harnessing the Body’s Own Defenses
TIL therapy represents a strategy that utilizes immune cells already present within the tumor microenvironment. These tumor-infiltrating lymphocytes, having been overwhelmed, can be extracted, expanded in a laboratory, and then reinfused into the patient to boost their immune response.
The FDA recently approved Amtagvi (lifileucel), marking a significant milestone as the first T-cell therapy approved for solid tumors. Ongoing studies are exploring its effectiveness in lung cancer, with early findings indicating that TIL therapy can lead to durable responses in patients with resistant cancers. The phase 2 IOV-LUN-202 study is currently enrolling patients who have progressed after chemo-immunotherapy without EGFR or ALK mutations.
Managing Side Effects of TIL Therapy
Patients undergoing TIL therapy may experience side effects related to the short course of chemotherapy preceding the infusion and subsequent immune activation. Common effects include low blood counts, heightened infection risk, nausea, fever, and fluid shifts. While these side effects are generally manageable and resolve within a few weeks, fatigue may linger longer.
TCR Therapy: Targeting Mutations with Precision
TCR therapy enhances the capabilities of T cells, enabling them to recognize and attack specific cancer targets within tumor cells. This personalized approach is contingent upon the patient’s HLA type, determining how immune cells present antigens.
Dr. Schoenfeld remarked that TCR therapy opens avenues for targeting key driver mutations previously inaccessible to traditional immunotherapies. The FDA’s approval of Tecelra (afamitresgene autoleucel) marks a significant development, with ongoing trials investigating TCR applications across various solid tumors, including those with the TP53 R175H mutation.
Side Effects of TCR Therapy
Similar to CAR-T therapy, TCR therapy can lead to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), both of which are manageable with established treatments. Most patients recover completely following the resolution of these inflammatory reactions.
CAR-T Therapy: Engineering Immune Superstars
CAR-T therapy involves modifying T cells with an antibody-derived “sensor” that allows them to detect surface targets on cancer cells, bypassing the need for a specific HLA type. This method enhances T cell activation and proliferation.
Progress in CAR-T therapy is particularly notable in small cell lung cancer (SCLC), where DLL3 expression is prevalent. The recent approval of DLL3-targeting bispecific antibodies has paved the way for evaluating CAR-T therapies in this context. For non-small cell lung cancer (NSCLC), identifying safe and effective surface targets remains a challenge, but initial studies are exploring engineered designs for improved specificity.
Managing Side Effects of CAR-T Therapy
The side effects associated with CAR-T therapy include CRS and ICANS, which can manifest as fever, low blood pressure, confusion, and other neurological symptoms. Dr. Schoenfeld assured that these responses are expected and manageable, allowing most patients to recover fully.
The Promise of Cell Therapies in Lung Cancer
Dr. Schoenfeld concluded that cellular therapies represent a transformative step towards personalized, durable cancer treatment. TIL therapy is leading the charge, supported by promising early data and active trials. Meanwhile, TCR and CAR-T therapies are rapidly advancing, especially in targeting driver mutations and SCLC. Although these therapies require meticulous preparation and monitoring, their potential to empower the immune system offers hope for more effective and lasting cancer treatments.
Key Takeaways
- Lung cancer treatment must be tailored to the unique biology of each tumor.
- TIL therapy is the first FDA-approved T-cell therapy for solid tumors, showing promise in lung cancer.
-
TCR therapy enables targeted attacks on specific mutations, expanding treatment options.
-
CAR-T therapy is evolving rapidly, particularly in small cell lung cancer, with ongoing trials exploring its effectiveness.
-
Side effects from these therapies are manageable and typically reversible, underscoring the need for careful patient monitoring.
In summary, the landscape of lung cancer treatment is evolving dramatically with the advent of cellular therapies, marking a new era in personalized medicine that holds great promise for patients.
Read more → www.curetoday.com